STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

Iowa Medicaid Drug Utilization Review (DUR) Commission

May 3, 2023

Location: **Teleconference** (Due to Federal PHE Declaration for the COVID-19 Pandemic)
Time: 9:30 a.m. – 1:30 p.m. CT

WebEx Meeting Link:
https://changehealthcare.webex.com/changehealthcare/j.php?MTID=m5ecb3a7fbd26a88f6e593c5f4a8e9856
Dial In: 1-844-621-3956
Meeting Number: 2532 397 0066
Meeting Password: YdcdGiVF623

Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the February 1, 2023 Meeting Minutes
    b) February 2023 DUR Recommendation Letter to DHHS
    c) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Amerigroup
    b) Iowa Total Care
    c) Fee-for-Service
    d) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure. Five (5) minute maximum limit.
    - Written - Must submit written comments and a completed conflict of interest disclosure.
    - Reference complete public comment policy here.
    - **All submissions must be received no later than 4:30 p.m. CT April 26, 2023.**
    - Send to info@iadur.org ***Indicate in email if providing written or verbal comment.***
6. Retrospective DUR
    a) Data Presentation(s)
        i. Contraindications to Metformin
        ii. Underutilization of SGLT2i in Type 2 Diabetes, Chronic Kidney Disease, and/or Heart Failure

b) Proposal(s)
    i. Antidepressants in Children
    ii. Metabolic Monitoring in Children and Adolescents on Antipsychotics
c) Commission Recommendations for Retrospective DUR Agenda Topics

7. Prospective DUR
    a) 90 Day Supply Limit – Second Review
8. Break (10 minutes)
9. Prior Authorization
    a) Palivizumab (Synagis) – Initial Review
    b) Naloxone Nasal Spray – Initial Review
    c) IL-5 Antagonists – Initial Review
    d) Select Anticonvulsants – Initial Review
    e) Cyclosporine Ophthalmic Emulsion (Verkazia) – Initial Review
    f) Topical Acne and Rosacea Products – Initial Review
    g) Viloxazine (Qelbree) – Second Review
    h) Dupilumab (Dupixent) – Second Review
    i) Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral – Second Review
    j) Janus Kinase Inhibitors – Second Review
10. Miscellaneous
    a) DUR Digest Vol. 35, No. 2 – Initial Review
    b) MedWatch

    FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis

    FDA approves first treatment for Friedreich's ataxia

    FDA approves first treatment for activated phosphoinositide 3-kinase delta syndrome

    FDA Approves First Over-the-Counter Naloxone Nasal Spray

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a conflict of interest disclosure. Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared. **www.iadur.org**

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515)974-3131.

Next Meeting
August 2, 2023
Location TBD